Edition:
United States

MorphoSys AG (MORG.DE)

MORG.DE on Xetra

99.95EUR
11:35am EDT
Change (% chg)

€1.15 (+1.16%)
Prev Close
€98.80
Open
€98.70
Day's High
€100.90
Day's Low
€98.70
Volume
96,287
Avg. Vol
121,985
52-wk High
€124.90
52-wk Low
€55.86

Latest Key Developments (Source: Significant Developments)

Morphosys AG Announces Appointment Of Jennifer Herron As President Of Morphosys Us Inc
Tuesday, 24 Jul 2018 04:01pm EDT 

July 24 (Reuters) - MorphoSys AG ::ANNOUNCES APPOINTMENT OF JENNIFER HERRON AS PRESIDENT OF MORPHOSYS US INC. AND EXECUTIVE VICE PRESIDENT, GLOBAL COMMERCIAL.HERRON WAS ALSO APPOINTED AS MEMBER OF THE BOARD OF DIRECTORS OF MORPHOSYS US INC.  Full Article

Morphosys AG Sees U.S. IPO 8.3 Mln American Depositary Shares - SEC Filing
Monday, 9 Apr 2018 07:54am EDT 

April 9 (Reuters) - MorphoSys AG ::MORPHOSYS AG SEES U.S. IPO 8.3 MLN AMERICAN DEPOSITARY SHARES - SEC FILING .MORPHOSYS AG SAYS OFFERING 8.3 MILLION ADSS, ASSUMING PUBLIC OFFERING PRICE OF $24.12 PER ADS.  Full Article

Morphosys Says Tremfya Approved To Treat Psoriasis In Japan
Friday, 6 Apr 2018 01:30am EDT 

April 6 (Reuters) - MorphoSys AG ::SAYS ANNOUNCES APPROVAL OF TREMFYA(R) (GUSELKUMAB) FOR THE TREATMENT OF MODERATE TO SEVERE FORMS OF PSORIASIS AND PSORIATIC ARTHRITIS IN JAPAN.  Full Article

Morphosys AG Files For U.S. IPO Of Up To $150 Mln
Thursday, 22 Mar 2018 03:18pm EDT 

March 22 (Reuters) - Morphosys AG::MORPHOSYS AG FILES FOR U.S. IPO OF UP TO $150 MILLION – SEC FILING.SAYS IT INTENDS TO APPLY TO HAVE ITS ADS LISTED ON THE NASDAQ UNDER THE SYMBOL "MOR".SAYS GOLDMAN SACHS & CO. LLC, J.P. MORGAN, LEERINK PARTNERS ARE AMONG UNDERWRITERS TO IPO.SAYS BERENBERG CAPITAL MARKETS LLC, JMP SECURITIES ARE AMONG UNDERWRITERS TO IPO.SAYS PROPOSED IPO PRICE IS AN ESTIMATE SOLELY FOR CALCULATING SEC REGISTRATION FEE.  Full Article

Morphosys AG Says ‍Files Registration Statement In United States For A Proposed American Depositary Shares (ADS) Offering​
Thursday, 22 Mar 2018 03:00pm EDT 

March 22 (Reuters) - Morphosys Ag ::SAYS ‍FILES REGISTRATION STATEMENT IN UNITED STATES FOR A PROPOSED AMERICAN DEPOSITARY SHARES (ADS) OFFERING​.SAYS ‍FINAL NUMBER OF ADSS TO BE OFFERED AND PRICE FOR OFFERING HAVE NOT YET BEEN DETERMINED​.  Full Article

Morphosys Sees EBIT Loss Widening To 110-120 Mln Euros In 2018
Tuesday, 13 Mar 2018 02:00am EDT 

March 13 (Reuters) - Morphosys AG ::‍REVENUES 2017 UP 34% TO EUR 66.8 MILLION (GUIDANCE EUR 63 TO 66 MILLION)​.‍EBIT LOSS 2017 AS EXPECTED AT EUR -67.6 MILLION (GUIDANCE EUR -66 TO -71 MILLION)‍.CONTINUES TO HAVE PRODUCTIVE DISCUSSIONS WITH FDA UNDER CURRENT BREAKTHROUGH THERAPY DESIGNATION ON PATH TO MARKET FOR MOR208.TALKS WITH FDA INCLUDE POSSIBILITY OF EXPEDITED REGULATORY SUBMISSION AND APPROVAL FOR MOR208 BASED PRIMARILY ON L-MIND STUDY​.SEES ‍2018 GROUP REVENUES IN RANGE OF EUR 20 TO 25 MILLION​.‍EXPECTS EARNINGS BEFORE INTEREST AND TAXES (EBIT) OF EUR -110 TO -120 MILLION IN 2018​.  Full Article

Morphosys And Galapagos Present Results From Phase 1 Study With Mor106
Monday, 19 Feb 2018 03:04am EST 

Feb 19 (Reuters) - MORPHOSYS AG ::SAID ON SATURDAY MORPHOSYS AND GALAPAGOS PRESENT RESULTS FROM A PHASE 1 STUDY WITH MOR106 IN ATOPIC DERMATITIS AS LATE-BREAKING ABSTRACT.IN THE STUDY, MOR106 WAS GENERALLY WELL TOLERATED IN ATOPIC DERMATITIS(AD)PATIENTS.83% OF PATIENTS (5 OUT OF 6) AT THE HIGHEST DOSE REACHED AT LEAST 50% IMPROVEMENT PER THE ATOPIC DERMATITIS AREA AND SEVERITY INDEX (EASI-50) AT WEEK 4.POOLED DATA ACROSS ALL DOSE COHORTS SHOWED 72% IMPROVEMENT OF AD SYMPTOMS AT WEEK 12 COMPARED TO BASELINE IN PATIENTS TREATED WITH MOR106.PHASE 2 DEVELOPMENT OF MOR106 PLANNED TO BE INITIATED IN FIRST HALF OF 2018.  Full Article

Morphosys Says Licensee Janssen Receives Approval For Tremfya In Canada
Tuesday, 5 Dec 2017 01:30am EST 

Dec 5 (Reuters) - MORPHOSYS AG ::DGAP-NEWS: MORPHOSYS ANNOUNCES THAT ITS LICENSEE JANSSEN HAS RECEIVED APPROVAL FOR TREMFYA(R) (GUSELKUMAB) FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN CANADA.MORPHOSYS IS ELIGIBLE TO RECEIVE ROYALTIES ON NET SALES OF TREMFYA.  Full Article

Morphosys Increases Financial Guidance For 2017
Thursday, 30 Nov 2017 05:02am EST 

Nov 30 (Reuters) - MORPHOSYS AG ::INCREASES FINANCIAL GUIDANCE FOR 2017 FOLLOWING SIGNATURE OF REGIONAL LICENSE AGREEMENT FOR ANTIBODY MOR202 WITH I-MAB.‍FOR YEAR 2017, MORPHOSYS NOW EXPECTS REVENUES IN RANGE FROM EUR 63 TO 66 MILLION​.NOW EXPECTS FY EBIT OF EUR -66 TO -71 MILLION (UP FROM PREVIOUSLY EUR -75 TO -85 MILLION).FY ‍PROPRIETARY RESEARCH AND DEVELOPMENT EXPENSES WILL BE IN RANGE FROM EUR 96 TO 100 MILLION (PREVIOUSLY EUR 85 TO 95 MILLION)​.RECEIVES AN IMMEDIATE UPFRONT PAYMENT OF USD 20 MILLION FROM LICENSE AGREEMENT SIGNED.WILL BE ENTITLED TO RECEIVE ADDITIONAL MILESTONE PAYMENTS FROM I-MAB OF UP TO C. USD 100 MILLION.TO BE ENTITLED TO RECEIVE TIERED, DOUBLE-DIGIT ROYALTIES ON NET SALES OF MOR202 IN TERRITORY.SHARES JUMP 5.2 PERCENT​.  Full Article

Janssen receives approval for Tremfya in Europe - Morphosys
Thursday, 23 Nov 2017 04:19am EST 

Nov 23 (Reuters) - Morphosys AG :Announces that its licensee Janssen has received approval for Tremfya(r) (guselkumab) in Europe for the treatment of moderate-to-severe plaque psoriasis.Says is ‍entitled to royalties on net sales of Janssen's Tremfya​.  Full Article

Photo

Novartis to pay 95 million euros to Galapagos, MorphoSys for skin drug

ZURICH Novartis said on Thursday it will pay 95 million euros ($110.49 million) to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its foothold in immunology.